STOCK TITAN
  1. Home
  2. News
  3. CYAD

Celyad Oncology - CYAD STOCK NEWS

Welcome to our dedicated news page for Celyad Oncology (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on Celyad Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celyad Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celyad Oncology's position in the market.

News
Celyad Oncology Announces the Termination of Its American Depository Receipt Program
Rhea-AI Summary
Celyad Oncology announces termination of its American Depository Receipt program, ADS holders can surrender their ADSs and receive underlying ordinary shares before October 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC
Rhea-AI Summary
Celyad Oncology received a rectified notification of transparency indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, now holds 29.99% of the company's shares and 27.53% voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SA
Rhea-AI Summary
Celyad Oncology received a transparency notification that Tolefi SA and related persons crossed the 20% threshold, holding 22.74% of the voting rights of the Company as of September 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
Rhea-AI Summary
CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, has acquired 29.99% of Celyad Oncology's shares and 27.53% voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC
Rhea-AI Summary
CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the threshold of 25%, holding 29.99% of Celyad Oncology's shares and 27.53% voting rights as of August 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Rhea-AI Summary
Celyad Oncology announces issuance of new shares, increasing share capital to 80,628,224.49 EUR
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Rhea-AI Summary
Celyad Oncology announces issuance of new shares, increasing share capital to 80,628,224.49 EUR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Celyad Oncology announces financial results and recent business developments for H1 2023. Georges Rawadi appointed CEO. Received €9.8m in private placement commitments. Progress in multiplex shRNA platform and NKG2D-based CAR T-cell platform. Cash and cash equivalents sufficient until Q4 2024. Decrease in R&D and G&A expenses. Net loss of €3.7m. Conference call scheduled for September 5th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical Shareholders
Rhea-AI Summary
Celyad Oncology announces commitments for capital increase of EUR 9.8 million at a subscription price of EUR 0.52 per share, representing a 5% discount to the 30-day VWAP. Proceeds will be used for research and development, pipeline advancement, and working capital. Fortress to hold 29.99% of share capital, Tolefi to hold approximately 16%. Additional capital increase planned for EUR 7.75 million, subject to approval. Company expects existing cash to be sufficient until end of Q4 2024. Fortress and Tolefi to have certain rights and lock-up obligations as part of the investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
Rhea-AI Summary
Celyad Oncology announces a capital increase of approximately EUR 9,800,000 with commitments from Fortress Investment Group and Tolefi SA. The subscription price of EUR 0.52 per share represents a 5% discount to the 30-day VWAP. The funds will be used for research and development, advancing the CAR-T pipeline, and working capital. Fortress will hold 29.99% of the Company's share capital and Tolefi will hold approximately 16% of the Company's share capital. The private placement and subsequent capital increase are expected to strengthen the Company's balance sheet and improve its cash position in the short term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock CYAD logo
Celyad Oncology

Nasdaq:CYAD

CYAD Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CYAD Stock Data

14.24M
13.58M
0.05%
29.15%
0.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Belgium
Mont Saint Guibert

About CYAD

founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).